Welcome!

News Feed Item

BD Announces Results For 2014 First Fiscal Quarter

-- Raises the bottom end of full fiscal year 2014 revenue and earnings ranges for guidance.

FRANKLIN LAKES, N.J., Feb. 4, 2014 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.0 billion for the first fiscal quarter ended December 31, 2013, representing an increase of 6.0 percent from the prior-year period, or 6.7 percent on a foreign currency-neutral basis. Revenue growth was aided, in part, by favorable timing of orders in the BD Medical and BD Diagnostics segments.

"Fiscal year 2014 is off to a strong start," said Vincent A. Forlenza, Chairman, CEO and President. "Our revenue and earnings growth exceeded our expectations and we have continuing confidence that we have built a solid foundation for future growth. Accordingly, we are raising the bottom end of our previous revenue and earnings ranges for our full fiscal year guidance."

First Quarter Earnings
Reported diluted earnings per share from continuing operations for the first quarter were $1.37 compared with $1.35 in the prior-year period, representing a 1.5 percent increase. On a foreign currency-neutral basis, diluted earnings per share from continuing operations for the first quarter increased by 8.1 percent. Adjusted diluted earnings per share from continuing operations excluding the medical device excise tax, which went into effect in January 2013 under the U.S. healthcare reform law, were $1.42, or an increase of 11.9 percent.

Segment Results
In the BD Medical segment, worldwide revenues for the quarter were $1.06 billion, representing an increase of 8.2 percent compared with the prior-year period, or an increase of 8.6 percent on a foreign currency-neutral basis. The segment's revenue growth reflects strong sales in the Medical Surgical Systems and Diabetes Care units and solid sales in the Pharmaceutical Systems unit. Both the Medical Surgical and Pharmaceutical Systems units also benefitted from favorable timing of orders.

In the BD Diagnostics segment, worldwide revenues for the quarter were $672 million, representing an increase of 3.1 percent compared with the prior-year period, or 4.2 percent on a foreign currency-neutral basis. The segment's growth was driven by international expansion in both the Preanalytical Systems and Diagnostic Systems business units. Diagnostic systems growth was also aided, in part, from a timing of flu orders.

In the BD Biosciences segment, worldwide revenues for the quarter were $279 million, representing an increase of 5.4 percent compared with the prior-year period, or an increase of 5.7 percent on a foreign currency-neutral basis. The segment's growth was driven by continued strength in emerging markets, clinical reagents sales and solid instrument placements in both the U.S. and Western Europe.

Geographic Results
First quarter revenues in the U.S. of $849 million represent an increase of 2.3 percent over the prior-year period. Revenues outside of the U.S. were $1.17 billion, representing an increase of 8.9 percent compared with the prior-year period, or an increase of 10.0 percent on a foreign currency-neutral basis. International revenues reflected continued strength in emerging markets and sales of safety-engineered products in addition to solid growth in Western Europe.

Fiscal 2014 Outlook for Full Year
The Company estimates that reported and currency-neutral revenues for the full fiscal year 2014 will increase 4.5 to 5.0 percent. The Company expects reported diluted earnings per share from continuing operations for the full fiscal year 2014 to be between $6.19 and $6.22, which represents growth of 6.5 to 7.0 percent over 2013 adjusted diluted earnings per share of $5.81.  On a foreign currency-neutral basis, adjusted diluted earnings per share are expected to grow about 9.0 to 9.5 percent, or 9.5 to 10.0 percent excluding the incremental impact of the medical device tax.  The Company plans to repurchase, subject to market conditions, about $450 million of its common stock in fiscal year 2014.

Conference Call Information
A conference call regarding BD's first quarter results will be broadcast live on BD's website, www.bd.com/investors, along with related slides, at 8:00 a.m. (ET) Tuesday, February 4th, 2014.  The conference call will be available for replay on BD's website, www.bd.com/investors, or at 1-800-585-8367 (domestic) and 1-404-537-3406 (international) through the close of business on Tuesday, February 11, 2014, confirmation number 31318159.

Non-GAAP Financial Measures/Financial Tables
This news release contains certain non-GAAP financial measures.  Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables.  Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers.  Percentages and earnings per share amounts presented are calculated from the underlying whole-dollar amounts.

About BD
BD is a leading medical technology company that partners with customers and stakeholders to address many of the world's most pressing and evolving health needs. Our innovative solutions are focused on improving drug delivery, enhancing the diagnosis of infectious diseases and cancers, supporting the management of diabetes and advancing cellular research. We are nearly 30,000 associates in 50 countries who strive to fulfill our purpose of "Helping all people live healthy lives" by advancing the quality, accessibility, safety and affordability of healthcare around the world. For more information, please visit www.bd.com.

This press release, including the section entitled "Fiscal 2014 Outlook for Full Year", contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues and earnings per share.  All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties.  Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement.  With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially from any forward-looking statement.  These factors include, but are not limited to: potential cuts in healthcare spending by the U.S. government as part of deficit reduction measures which could result in reduced demand for our product or downward pricing pressure; the unknown consequences of healthcare reform in the United States, including the impact of the reduction in Medicare and Medicaid payments to hospitals, pharmaceutical companies and other customers, which could reduce demand for our products and increase downward pricing pressure; adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic conditions on our ability to access credit markets and finance our operations, the demand for our products and services as a result of reduced government funding, lower utilization rates or otherwise, or our suppliers' ability to provide products needed for our operations; changes in interest or foreign currency exchange rates; our ability to successfully integrate any businesses we acquire; the adverse impact of cyber-attacks on our information systems; competitive factors; pricing and market pressures; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; new or changing laws impacting our business or changes in enforcement practices with respect to such laws; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); future healthcare reform, including changes in government pricing and reimbursement policies or other cost containment reforms; the effects of potential pandemic diseases; and issuance of new or revised accounting standards, as well as other factors discussed in BD's filings with the Securities and Exchange Commission.  We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

Contact:
Monique N. Dolecki, Investor Relations – 201-847-5453
Alyssa J. Zeff, Corporate Communications – 201-847-4358

 

BECTON DICKINSON AND COMPANY


CONSOLIDATED INCOME STATEMENTS


(Unaudited; Amounts in millions, except share and per share data)











Three Months Ended December 31,



2013


2012


% Change










REVENUES

$

2,015

$

1,900


6.0










Cost of products sold


980


894


9.6


Selling and administrative 


531


496


7.1


Research and development


126


118


6.4


TOTAL OPERATING COSTS








     AND EXPENSES


1,637


1,508


8.5










OPERATING INCOME


378


392


(3.6)










Interest income


14


8


75.7


Interest expense


(34)


(35)


(4.3)


Other income, net


1


1


(14.0)










INCOME FROM CONTINUING OPERATIONS BEFORE








     INCOME TAXES


359


366


(1.9)










Income tax provision


88


95


(8.3)










INCOME FROM CONTINUING OPERATIONS


271


270


0.4










INCOME FROM DISCONTINUED OPERATIONS








   NET OF INCOME TAX PROVISION OF








   $0 AND $216, RESPECTIVELY


-


355


        NM 










NET INCOME

$

271

$

625


(56.6)










EARNINGS PER SHARE
















Basic:








Income from continuing operations

$

1.40

$

1.38


1.4


Income from discontinued operations

$

-

$

1.81


        NM 


Net income 

$

1.40

$

3.18


(56.0)










Diluted:








Income from continuing operations

$

1.37

$

1.35


1.5


Income from discontinued operations

$

-

$

1.78


        NM 


Net income 

$

1.37

$

3.13


(56.2)


















AVERAGE SHARES OUTSTANDING (in thousands)
















     Basic


194,203


196,427




     Diluted


198,110


199,570












NM - Not Meaningful








 

BECTON DICKINSON AND COMPANY


SUPPLEMENTAL REVENUE INFORMATION


REVENUES BY SEGMENT AND GEOGRAPHIC AREA


(Unaudited; Amounts in millions)











Three Months Ended December 31,



2013


2012


% Change










BD MEDICAL








   United States

$

441

$

425


3.8


   International


622


558


11.5


TOTAL

$

1,064

$

983


8.2










BD DIAGNOSTICS








   United States

$

321

$

321


0.1


   International


351


331


6.0


TOTAL

$

672

$

652


3.1










BD BIOSCIENCES








   United States

$

87

$

84


3.3


   International


192


181


6.3


TOTAL

$

279

$

265


5.4










TOTAL REVENUES








   United States

$

849

$

830


2.3


   International


1,166


1,070


8.9


TOTAL

$

2,015

$

1,900


6.0


 

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Three Months Ended December 31,

(Unaudited; Amounts in millions)









United States



2013


2012


 % Change 








BD MEDICAL







   Medical Surgical Systems

$

262

$

249


5.3

   Diabetes Care


122


112


8.4

   Pharmaceutical Systems


57


64


(10.4)

TOTAL

$

441

$

425


3.8








BD DIAGNOSTICS







   Preanalytical Systems

$

171

$

167


2.7

   Diagnostic Systems


149


154


(2.7)

TOTAL

$

321

$

321


0.1








BD BIOSCIENCES

$

87

$

84


3.3








TOTAL UNITED STATES

$

849

$

830


2.3

 

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Three Months Ended December 31, (continued)

(Unaudited; Amounts in millions)













International







 % Change 



2013


2012


 Reported 


FXN


FX Impact












BD MEDICAL











   Medical Surgical Systems

$

317

$

287


10.4


12.4


(2.0)

   Diabetes Care


142


130


8.7


11.5


(2.8)

   Pharmaceutical Systems


164


141


16.4


12.6


3.8

TOTAL

$

622

$

558


11.5


12.2


(0.7)












BD DIAGNOSTICS











   Preanalytical Systems

$

176

$

168


4.8


6.1


(1.3)

   Diagnostic Systems


175


164


7.2


10.2


(3.0)

TOTAL

$

351

$

331


6.0


8.1


(2.1)












BD BIOSCIENCES

$

192

$

181


6.3


6.8


(0.5)












TOTAL INTERNATIONAL

$

1,166

$

1,070


8.9


10.0


(1.1)

 

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Three Months Ended December 31, (continued)

(Unaudited; Amounts in millions)













Total







 % Change 



2013


2012


 Reported 


FXN


FX Impact












BD MEDICAL 











   Medical Surgical Systems

$

579

$

536


8.0


9.1


(1.1)

   Diabetes Care


264


243


8.6


10.1


(1.5)

   Pharmaceutical Systems


221


205


8.0


5.5


2.5

TOTAL

$

1,064

$

983


8.2


8.6


(0.4)












BD DIAGNOSTICS











   Preanalytical Systems

$

347

$

335


3.7


4.4


(0.7)

   Diagnostic Systems


325


317


2.4


3.9


(1.5)

TOTAL

$

672

$

652


3.1


4.2


(1.1)












BD BIOSCIENCES

$

279

$

265


5.4


5.7


(0.3)












TOTAL REVENUES

$

2,015

$

1,900


6.0


6.7


(0.7)

 

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

SAFETY REVENUES

(Unaudited; Amounts in millions)













Three Months Ended December 31,







 % Change 



2013


2012


 Reported 


FXN


FX Impact












TOTAL SAFETY REVENUES











   United States

$

315

$

291


8.1


8.1


-

   International


242


220


10.1


12.0


(1.9)

TOTAL

$

557

$

511


9.0


9.8


(0.8)












BY SEGMENT











   BD Medical

$

285

$

252


13.0


14.0


(1.0)

   BD Diagnostics


272


259


5.0


5.7


(0.7)

TOTAL

$

557

$

511


9.0


9.8


(0.8)

 

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

FY2014 Quarter-to-Date Reconciliation of Non-GAAP Financial Measures

(Unaudited)

















Three Months Ended December 31,



2013


2012


Growth


Foreign Currency Translation


Foreign Currency Neutral Change


Growth %


Foreign Currency Neutral Growth %
















Reported Diluted Earnings per Share from Continuing Operations

$

1.37

$

1.35

$

0.02

$

(0.09)

$

0.11


1.5%


8.1%
















Medical device excise tax which went into effect in January 2013 under the U.S. Patient Protection and Affordable Care Act
($14 million or $9 million after-tax)


0.05


0.00


























Adjusted Diluted Earnings per Share from Continuing Operations without Medical Device Excise Tax

$

1.42

$

1.35

$

0.07

$

(0.09)

$

0.16


5.2%


11.9%

 

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

FY2014 Outlook Reconciliation










Reported







Basis


FX Impact


FXN Basis








Revenues - Full Year 2014 estimated growth


4.5% - 5.0%


0.0%


4.5% - 5.0%













































Full Year


Full Year





2014


2013


% Increase



(estimated)





Reported Fully Diluted Earnings per Share 







from Continuing Operations

$

6.19 - 6.22

$

4.67


NM








Pending Litigation Settlement (1)




0.07










Verdict Charge (2)




1.06










Pension Settlement Charge (3)




0.02










Adjusted Fully Diluted Earnings per Share 







from Continuing Operations

$

6.19 - 6.22

$

5.81


6.5% - 7.0%








FX Impact






(2.5%)








Adjusted FXN Growth






9.0% - 9.5%








Medical Device Excise Tax Impact (4)






(0.5%)








Adjusted FXN Growth (excluding the medical device excise tax)






9.5% - 10.0%

 

(1) Charge associated with the pending litigation settlement related to indirect purchaser antitrust class action cases.












(2) Charge associated with the unfavorable verdict returned in the antitrust and false advertising lawsuit filed against the Company by RTI.












(3) Represents a non-cash pension settlement charge associated with lump sum benefit payments made from the Company's U.S. supplemental pension plan, as such payments exceeded the service and interest components of the plan's pension cost for the year. The charge also included settlement losses associated with certain foreign pension plans.












(4) Represents the incremental impact of the medical device excise tax in first quarter fiscal year 2014 (tax went into effect in January 2013 under the U.S. Patient Protection and Affordable Care Act).























NM - Not Meaningful











FXN = Foreign Currency Neutral











 

SOURCE BD (Becton, Dickinson and Company)

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Every successful software product evolves from an idea to an enterprise system. Notably, the same way is passed by the product owner's company. In his session at 20th Cloud Expo, Oleg Lola, CEO of MobiDev, will provide a generalized overview of the evolution of a software product, the product owner, the needs that arise at various stages of this process, and the value brought by a software development partner to the product owner as a response to these needs.
SYS-CON Events announced today that delaPlex will exhibit at SYS-CON's @ThingsExpo, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. delaPlex pioneered Software Development as a Service (SDaaS), which provides scalable resources to build, test, and deploy software. It’s a fast and more reliable way to develop a new product or expand your in-house team.
SYS-CON Events announced today that Tappest will exhibit MooseFS at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. MooseFS is a breakthrough concept in the storage industry. It allows you to secure stored data with either duplication or erasure coding using any server. The newest – 4.0 version of the software enables users to maintain the redundancy level with even 50% less hard drive space required. The software func...
Most technology leaders, contemporary and from the hardware era, are reshaping their businesses to do software in the hope of capturing value in IoT. Although IoT is relatively new in the market, it has already gone through many promotional terms such as IoE, IoX, SDX, Edge/Fog, Mist Compute, etc. Ultimately, irrespective of the name, it is about deriving value from independent software assets participating in an ecosystem as one comprehensive solution.
SYS-CON Events announced today that EARP will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. "We are a software house, so we perfectly understand challenges that other software houses face in their projects. We can augment a team, that will work with the same standards and processes as our partners' internal teams. Our teams will deliver the same quality within the required time and budget just as our partn...
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
SYS-CON Events announced today that Systena America will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Systena Group has been in business for various software development and verification in Japan, US, ASEAN, and China by utilizing the knowledge we gained from all types of device development for various industries including smartphones (Android/iOS), wireless communication, security technology and IoT serv...
SYS-CON Events announced today that Outscale will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Outscale's technology makes an automated and adaptable Cloud available to businesses, supporting them in the most complex IT projects while controlling their operational aspects. You boost your IT infrastructure's reactivity, with request responses that only take a few seconds.
Regardless of what business you’re in, it’s increasingly a software-driven business. Consumers’ rising expectations for connected digital and physical experiences are driving what some are calling the "Customer Experience Challenge.” In his session at @DevOpsSummit at 20th Cloud Expo, Marco Morales, Director of Global Solutions at CollabNet, will discuss how organizations are increasingly adopting a discipline of Value Stream Mapping to ensure that the software they are producing is poised to o...
DevOps at Cloud Expo – being held October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises – and delivering real r...
Cloud applications are seeing a deluge of requests to support the exploding advanced analytics market. “Open analytics” is the emerging strategy to deliver that data through an open data access layer, in the cloud, to be directly consumed by external analytics tools and popular programming languages. An increasing number of data engineers and data scientists use a variety of platforms and advanced analytics languages such as SAS, R, Python and Java, as well as frameworks such as Hadoop and Spark...
Interested in leveling up on your Cloud Foundry skills? Join IBM for Cloud Foundry Days on June 7 at Cloud Expo New York at the Javits Center in New York City. Cloud Foundry Days is a free half day educational conference and networking event. Come find out why Cloud Foundry is the industry's fastest-growing and most adopted cloud application platform.
Cloud promises the agility required by today’s digital businesses. As organizations adopt cloud based infrastructures and services, their IT resources become increasingly dynamic and hybrid in nature. Managing these require modern IT operations and tools. In his session at 20th Cloud Expo, Raj Sundaram, Senior Principal Product Manager at CA Technologies, will discuss how to modernize your IT operations in order to proactively manage your hybrid cloud and IT environments. He will be sharing bes...
SYS-CON Events announced today that delaPlex will exhibit at SYS-CON's @CloudExpo, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. delaPlex pioneered Software Development as a Service (SDaaS), which provides scalable resources to build, test, and deploy software. It’s a fast and more reliable way to develop a new product or expand your in-house team.
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...